메뉴 건너뛰기




Volumn 75, Issue 18, 2015, Pages 2065-2071

Disease-Modifying Drugs in Parkinson's Disease

Author keywords

[No Author keywords available]

Indexed keywords

AFFITOPE; ALPHA SYNUCLEIN; CREATINE; EXENDIN 4; ISRADIPINE; NEUROPROTECTIVE AGENT; NICOTINE; PIOGLITAZONE; RASAGILINE; SAFINAMIDE; SELEGILINE; UBIDECARENONE; UNCLASSIFIED DRUG; URATE; ANTIPARKINSON AGENT; BIOLOGICAL MARKER;

EID: 84949024608     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0497-4     Document Type: Article
Times cited : (31)

References (64)
  • 1
    • 33846572874 scopus 로고    scopus 로고
    • Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    • 1:STN:280:DC%2BD2s%2FlsFOmug%3D%3D 17082464
    • Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.
    • (2007) Neurology. , vol.68 , Issue.5 , pp. 384-386
    • Dorsey, E.R.1    Constantinescu, R.2    Thompson, J.P.3    Biglan, K.M.4    Holloway, R.G.5    Kieburtz, K.6
  • 2
    • 0017082987 scopus 로고
    • Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis
    • 1:CAS:528:DyaE28XlsVSqtb4%3D 956814
    • Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38(3-4):277-301.
    • (1976) J Neural Transm , vol.38 , Issue.3-4 , pp. 277-301
    • Riederer, P.1    Wuketich, S.2
  • 3
    • 84938948969 scopus 로고    scopus 로고
    • New clinical subtypes of Parkinson disaese and their longitudinal progression: A prospective cohort comparison with other phenotypes
    • 26076039
    • Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disaese and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-73.
    • (2015) JAMA Neurol. , vol.72 , Issue.8 , pp. 863-873
    • Fereshtehnejad, S.M.1    Romenets, S.R.2    Anang, J.B.3    Latreille, V.4    Gagnon, J.F.5    Postuma, R.B.6
  • 4
    • 0031668934 scopus 로고    scopus 로고
    • The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
    • 1:CAS:528:DyaK1cXmtFGktb8%3D 9749592
    • Marsden CD, Olanow CW. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol. 1998;44(3 Suppl 1):S189-96.
    • (1998) Ann Neurol , vol.44 , Issue.3 , pp. S189-S196
    • Marsden, C.D.1    Olanow, C.W.2
  • 5
    • 0141741347 scopus 로고    scopus 로고
    • Parkinson's disease: Mechanisms and models
    • 1:CAS:528:DC%2BD3sXnsFait7o%3D 12971891
    • Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909.
    • (2003) Neuron , vol.39 , Issue.6 , pp. 889-909
    • Dauer, W.1    Przedborski, S.2
  • 6
    • 84873443346 scopus 로고    scopus 로고
    • Parkinson's disease: Evidence for environmental risk factors
    • 1:CAS:528:DC%2BC3sXjsVWhtrw%3D
    • Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord Off J Mov Disord Soc. 2013;28(1):8-13.
    • (2013) Mov Disord off J Mov Disord Soc , vol.28 , Issue.1 , pp. 8-13
    • Kieburtz, K.1    Wunderle, K.B.2
  • 7
    • 84873478145 scopus 로고    scopus 로고
    • Trial designs used to study neuroprotective therapy in Parkinson's disease
    • 1:CAS:528:DC%2BC3sXjsVWht74%3D
    • Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2013;28(1):86-95.
    • (2013) Mov Disord off J Mov Disord Soc , vol.28 , Issue.1 , pp. 86-95
    • Lang, A.E.1    Melamed, E.2    Poewe, W.3    Rascol, O.4
  • 8
    • 0037461309 scopus 로고    scopus 로고
    • Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
    • 1:STN:280:DC%2BD3s7ovVKitg%3D%3D 12707423
    • Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234-40.
    • (2003) Neurology. , vol.60 , Issue.8 , pp. 1234-1240
    • Ravina, B.M.1    Fagan, S.C.2    Hart, R.G.3    Hovinga, C.A.4    Murphy, D.D.5    Dawson, T.M.6
  • 9
    • 0036719861 scopus 로고    scopus 로고
    • Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes
    • 1:CAS:528:DC%2BD38XmsVCit7c%3D 12200198
    • Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24(5):675-82.
    • (2002) Neurotoxicol Teratol , vol.24 , Issue.5 , pp. 675-682
    • Maruyama, W.1    Akao, Y.2    Carrillo, M.C.3    Kitani, K.4    Youdium, M.B.5    Naoi, M.6
  • 10
    • 0024457355 scopus 로고
    • A multicenter controlled clinical trial in early Parkinson's disease
    • Parkinson Study Group. Arch Neurol.
    • DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol. 1989;46(10):1052'60.
    • (1989) DATATOP , vol.46 , Issue.10 , pp. 1052-1060
  • 11
    • 0024456653 scopus 로고
    • Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. New Engl
    • Parkinson Study Group
    • Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. New Engl. J Med. 1989;321(20):1364-71.
    • (1989) J Med. , vol.321 , Issue.20 , pp. 1364-1371
  • 12
    • 0027530638 scopus 로고
    • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
    • Parkinson Study Group
    • Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med. 1993;328(3):176-83.
    • (1993) New Engl J Med. , vol.328 , Issue.3 , pp. 176-183
  • 13
    • 0028858370 scopus 로고
    • The effect of deprenyl and levodopa on the progression of Parkinson's disease
    • 1:CAS:528:DyaK28XlsVWhug%3D%3D 7486869
    • Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995;38(5):771-7.
    • (1995) Ann Neurol. , vol.38 , Issue.5 , pp. 771-777
    • Olanow, C.W.1    Hauser, R.A.2    Gauger, L.3    Malapira, T.4    Koller, W.5    Hubble, J.6
  • 15
    • 0036894795 scopus 로고    scopus 로고
    • A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study
    • Parkinson Study Group
    • Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-43.
    • (2002) Arch Neurol. , vol.59 , Issue.12 , pp. 1937-1943
  • 16
    • 13444302612 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study
    • Parkinson Study Group
    • Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-8.
    • (2005) Arch Neurol. , vol.62 , Issue.2 , pp. 241-248
  • 17
    • 15844386001 scopus 로고    scopus 로고
    • Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
    • 1:CAS:528:DC%2BD2MXitlOhtL8%3D 15766996
    • Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-54.
    • (2005) Lancet , vol.365 , Issue.9463 , pp. 947-954
    • Rascol, O.1    Brooks, D.J.2    Melamed, E.3    Oertel, W.4    Poewe, W.5    Stocchi, F.6
  • 18
    • 0034738387 scopus 로고    scopus 로고
    • Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline
    • 1:CAS:528:DC%2BD3cXmtlGktr4%3D 10996018
    • Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116(2-3):181-91.
    • (2000) Mech Ageing Dev , vol.116 , Issue.2-3 , pp. 181-191
    • Maruyama, W.1    Yamamoto, T.2    Kitani, K.3    Carrillo, M.C.4    Youdim, M.5    Naoi, M.6
  • 19
    • 0032999575 scopus 로고    scopus 로고
    • Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
    • 1:CAS:528:DyaK1MXhtFaru7w%3D 10082192
    • Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366(2-3):127-35.
    • (1999) Eur J Pharmacol , vol.366 , Issue.2-3 , pp. 127-135
    • Huang, W.1    Chen, Y.2    Shohami, E.3    Weinstock, M.4
  • 20
    • 12244296145 scopus 로고    scopus 로고
    • Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
    • 1:CAS:528:DC%2BD2MXltlCltA%3D%3D 15573406
    • Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79(1-2):172-9.
    • (2005) J Neurosci Res , vol.79 , Issue.1-2 , pp. 172-179
    • Youdim, M.B.1    Bar Am, O.2    Yogev-Falach, M.3    Weinreb, O.4    Maruyama, W.5    Naoi, M.6
  • 21
    • 2342655732 scopus 로고    scopus 로고
    • A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease
    • Parkinson Study Group
    • Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-6.
    • (2004) Arch Neurol. , vol.61 , Issue.4 , pp. 561-566
  • 23
    • 61449173973 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
    • Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord Off J Mov Disord Soc. 2008;23(15):2194-201.
    • (2008) Mov Disord off J Mov Disord Soc , vol.23 , Issue.15 , pp. 2194-2201
    • Olanow, C.W.1    Hauser, R.A.2    Jankovic, J.3    Langston, W.4    Lang, A.5    Poewe, W.6
  • 24
    • 70349456475 scopus 로고    scopus 로고
    • A double-blind, delayed-start trial of rasagiline in Parkinson's disease
    • 1:CAS:528:DC%2BD1MXht1Wjt7rK 19776408
    • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New Engl J Med. 2009;361(13):1268-78.
    • (2009) New Engl J Med. , vol.361 , Issue.13 , pp. 1268-1278
    • Olanow, C.W.1    Rascol, O.2    Hauser, R.3    Feigin, P.D.4    Jankovic, J.5    Lang, A.6
  • 25
    • 33750026173 scopus 로고    scopus 로고
    • Safinamide: From molecular targets to a new anti-Parkinson drug
    • 1:CAS:528:DC%2BD28XhtVeqsLfL 17030736
    • Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18-23.
    • (2006) Neurology. , vol.67 , Issue.7 , pp. S18-S23
    • Caccia, C.1    Maj, R.2    Calabresi, M.3    Maestroni, S.4    Faravelli, L.5    Curatolo, L.6
  • 26
    • 84855957418 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
    • 1:CAS:528:DC%2BC38XhsVWmsL7J
    • Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord Off J Mov Disord Soc. 2012;27(1):106-12.
    • (2012) Mov Disord off J Mov Disord Soc , vol.27 , Issue.1 , pp. 106-112
    • Stocchi, F.1    Borgohain, R.2    Onofrj, M.3    Schapira, A.H.4    Bhatt, M.5    Lucini, V.6
  • 28
    • 84894251130 scopus 로고    scopus 로고
    • Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
    • 1:CAS:528:DC%2BC2cXjt1ymsL4%3D
    • Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord Off J Mov Disord Soc. 2014;29(2):229-37.
    • (2014) Mov Disord off J Mov Disord Soc , vol.29 , Issue.2 , pp. 229-237
    • Borgohain, R.1    Szasz, J.2    Stanzione, P.3    Meshram, C.4    Bhatt, M.5    Chirilineau, D.6
  • 29
    • 0024848034 scopus 로고
    • Abnormalities of the electron transport chain in idiopathic Parkinson's disease
    • 2557792
    • Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26(6):719-23.
    • (1989) Ann Neurol. , vol.26 , Issue.6 , pp. 719-723
    • Parker, W.D.1    Boyson, S.J.2    Parks, J.K.3
  • 30
    • 0033001416 scopus 로고    scopus 로고
    • A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease
    • 1:CAS:528:DyaK1MXkt12mtr8%3D 10416040
    • Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. BioFactors. 1999;9(2-4):267-72.
    • (1999) BioFactors , vol.9 , Issue.2-4 , pp. 267-272
    • Shults, C.W.1    Haas, R.H.2    Beal, M.F.3
  • 31
    • 0036771852 scopus 로고    scopus 로고
    • Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline
    • 12374491
    • Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-50.
    • (2002) Arch Neurol , vol.59 , Issue.10 , pp. 1541-1550
    • Shults, C.W.1    Oakes, D.2    Kieburtz, K.3    Beal, M.F.4    Haas, R.5    Plumb, S.6
  • 32
    • 84900479240 scopus 로고    scopus 로고
    • A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit
    • 24664227
    • Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-52.
    • (2014) JAMA Neurol , vol.71 , Issue.5 , pp. 543-552
    • Beal, M.F.1    Oakes, D.2    Shoulson, I.3    Henchcliffe, C.4    Galpern, W.R.5    Haas, R.6
  • 33
    • 0035002174 scopus 로고    scopus 로고
    • Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders
    • 1:CAS:528:DC%2BD3MXjvFKhu7k%3D 11357946
    • Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49(5):561-74.
    • (2001) Ann Neurol. , vol.49 , Issue.5 , pp. 561-574
    • Tarnopolsky, M.A.1    Beal, M.F.2
  • 35
    • 33645894705 scopus 로고    scopus 로고
    • A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
    • NINDS NET-PD Investigators
    • NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-71.
    • (2006) Neurology. , vol.66 , Issue.5 , pp. 664-671
  • 36
    • 84922485882 scopus 로고    scopus 로고
    • Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial
    • 25668262
    • Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584-93.
    • (2015) JAMA , vol.313 , Issue.6 , pp. 584-593
    • Kieburtz, K.1    Tilley, B.C.2    Elm, J.J.3    Babcock, D.4    Hauser, R.5    Ross, G.W.6
  • 37
    • 34347359673 scopus 로고    scopus 로고
    • 'Rejuvenation' protects neurons in mouse models of Parkinson's disease
    • 1:CAS:528:DC%2BD2sXmvFKmurY%3D 17558391
    • Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007;447(7148):1081-6.
    • (2007) Nature , vol.447 , Issue.7148 , pp. 1081-1086
    • Chan, C.S.1    Guzman, J.N.2    Ilijic, E.3    Mercer, J.N.4    Rick, C.5    Tkatch, T.6
  • 38
    • 0030601952 scopus 로고    scopus 로고
    • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
    • 1:CAS:528:DyaK28XmvFaktr8%3D 9001722
    • Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996;741(1-2):185-96.
    • (1996) Brain Res , vol.741 , Issue.1-2 , pp. 185-196
    • Kupsch, A.1    Sautter, J.2    Schwarz, J.3    Riederer, P.4    Gerlach, M.5    Oertel, W.H.6
  • 39
    • 79958204001 scopus 로고    scopus 로고
    • The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
    • 3235730 1:CAS:528:DC%2BC3MXnsFWhu70%3D 21515375
    • Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011;43(2):364-71.
    • (2011) Neurobiol Dis , vol.43 , Issue.2 , pp. 364-371
    • Ilijic, E.1    Guzman, J.N.2    Surmeier, D.J.3
  • 40
    • 77951735527 scopus 로고    scopus 로고
    • L-type calcium channel blockers and Parkinson disease in Denmark
    • 2917467 1:CAS:528:DC%2BC3cXmvF2lsrw%3D 20437557
    • Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600-6.
    • (2010) Ann Neurol. , vol.67 , Issue.5 , pp. 600-606
    • Ritz, B.1    Rhodes, S.L.2    Qian, L.3    Schernhammer, E.4    Olsen, J.H.5    Friis, S.6
  • 43
    • 84887625913 scopus 로고    scopus 로고
    • Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
    • 1:CAS:528:DC%2BC3sXhsl2hur%2FO
    • Simuni T, Biglan K, Oakes D, et al. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord Off J Mov Disord Soc. 2013;28(13):1823-31.
    • (2013) Mov Disord off J Mov Disord Soc. , vol.28 , Issue.13 , pp. 1823-1831
    • Simuni, T.1    Biglan, K.2    Oakes, D.3
  • 46
    • 45149122797 scopus 로고    scopus 로고
    • Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    • 2574855 18413464
    • Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23.
    • (2008) Arch Neurol , vol.65 , Issue.6 , pp. 716-723
    • Schwarzschild, M.A.1    Schwid, S.R.2    Marek, K.3    Watts, A.4    Lang, A.E.5    Oakes, D.6
  • 47
    • 73549111772 scopus 로고    scopus 로고
    • Urate as a predictor of the rate of clinical decline in Parkinson disease
    • 2795011 19822770
    • Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-8.
    • (2009) Arch Neurol , vol.66 , Issue.12 , pp. 1460-1468
    • Ascherio, A.1    LeWitt, P.A.2    Xu, K.3    Eberly, S.4    Watts, A.5    Matson, W.R.6
  • 48
    • 84893841038 scopus 로고    scopus 로고
    • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial
    • 24366103
    • Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141-50.
    • (2014) JAMA Neurol , vol.71 , Issue.2 , pp. 141-150
    • Schwarzschild, M.A.1    Ascherio, A.2    Beal, M.F.3    Cudkowicz, M.E.4    Curhan, G.C.5    Hare, J.M.6
  • 49
    • 0347087323 scopus 로고    scopus 로고
    • Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation
    • 1:CAS:528:DC%2BD2cXntlWjug%3D%3D 14690537
    • Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004;88(2):494-501.
    • (2004) J Neurochem , vol.88 , Issue.2 , pp. 494-501
    • Dehmer, T.1    Heneka, M.T.2    Sastre, M.3    Dichgans, J.4    Schulz, J.B.5
  • 50
    • 79961103714 scopus 로고    scopus 로고
    • The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
    • 1:CAS:528:DC%2BC3MXhtFegsbfP
    • Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflamm. 2011;8:91.
    • (2011) J Neuroinflamm , vol.8 , pp. 91
    • Swanson, C.R.1    Joers, V.2    Bondarenko, V.3    Brunner, K.4    Simmons, H.A.5    Ziegler, T.E.6
  • 52
    • 59049087723 scopus 로고    scopus 로고
    • GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
    • 2633544 1:CAS:528:DC%2BD1MXhsFyiurc%3D 19164583
    • Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285-90.
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.4 , pp. 1285-1290
    • Li, Y.1    Perry, T.2    Kindy, M.S.3    Harvey, B.K.4    Tweedie, D.5    Holloway, H.W.6
  • 53
    • 45549108268 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
    • Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflamm. 2008;5:19.
    • (2008) J Neuroinflamm , vol.5 , pp. 19
    • Harkavyi, A.1    Abuirmeileh, A.2    Lever, R.3    Kingsbury, A.E.4    Biggs, C.S.5    Whitton, P.S.6
  • 54
    • 84904126994 scopus 로고    scopus 로고
    • Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
    • 1:CAS:528:DC%2BC2cXhvFeit7%2FP
    • Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinson's Dis. 2014;4(3):337-44.
    • (2014) J Parkinson's Dis , vol.4 , Issue.3 , pp. 337-344
    • Aviles-Olmos, I.1    Dickson, J.2    Kefalopoulou, Z.3    Djamshidian, A.4    Kahan, J.5    Ell, P.6
  • 56
    • 4444230502 scopus 로고    scopus 로고
    • Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: Systematic review of prospective studies
    • Allam MF, Campbell MJ, Hofman A, Del Castillo AS. Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord Off J Mov Disord Soc. 2004;19(6):614-21.
    • (2004) Mov Disord off J Mov Disord Soc , vol.19 , Issue.6 , pp. 614-621
    • Allam, M.F.1    Campbell, M.J.2    Hofman, A.3    Del, C.A.4
  • 57
    • 33947546011 scopus 로고    scopus 로고
    • Temporal relationship between cigarette smoking and risk of Parkinson disease
    • 2225169 1:CAS:528:DC%2BD2sXitFyqsbY%3D 17339584
    • Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68(10):764-8.
    • (2007) Neurology. , vol.68 , Issue.10 , pp. 764-768
    • Thacker, E.L.1    O'Reilly, E.J.2    Weisskopf, M.G.3    Chen, H.4    Schwarzschild, M.A.5    McCullough, M.L.6
  • 58
    • 0026327733 scopus 로고
    • Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: A microdialysis study
    • 1:STN:280:DyaK383ntVWhtw%3D%3D 1815152
    • Janson AM, Meana JJ, Goiny M, Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett. 1991;134(1):88-92.
    • (1991) Neurosci Lett , vol.134 , Issue.1 , pp. 88-92
    • Janson, A.M.1    Meana, J.J.2    Goiny, M.3    Herrera-Marschitz, M.4
  • 59
    • 33748159130 scopus 로고    scopus 로고
    • Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates
    • 1:CAS:528:DC%2BD28XhtVCksb7I 16882311
    • Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006;98(6):1866-75.
    • (2006) J Neurochem , vol.98 , Issue.6 , pp. 1866-1875
    • Quik, M.1    Parameswaran, N.2    McCallum, S.E.3    Bordia, T.4    Bao, S.5    McCormack, A.6
  • 60
    • 0037185083 scopus 로고    scopus 로고
    • Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture
    • 1:CAS:528:DC%2BD38XktVKlsQ%3D%3D 11801364
    • Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience. 2002;109(2):275-85.
    • (2002) Neuroscience , vol.109 , Issue.2 , pp. 275-285
    • Jeyarasasingam, G.1    Tompkins, L.2    Quik, M.3
  • 61
    • 0037382337 scopus 로고    scopus 로고
    • Nicotine protects rat brain mitochondria against experimental injuries
    • 1:CAS:528:DC%2BD3sXisFWnsL4%3D 12668050
    • Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology. 2003;44(5):642-52.
    • (2003) Neuropharmacology , vol.44 , Issue.5 , pp. 642-652
    • Cormier, A.1    Morin, C.2    Zini, R.3    Tillement, J.P.4    Lagrue, G.5
  • 62
    • 69149089854 scopus 로고    scopus 로고
    • Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein
    • 2722313 1:CAS:528:DC%2BD1MXhtVKru7%2FM 19651612
    • Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. 2009;106(31):13010-5.
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.31 , pp. 13010-13015
    • Desplats, P.1    Lee, H.J.2    Bae, E.J.3    Patrick, C.4    Rockenstein, E.5    Crews, L.6
  • 63
    • 84869109864 scopus 로고    scopus 로고
    • Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice
    • 3552321 1:CAS:528:DC%2BC38Xhs1GntL7L 23161999
    • Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949-53.
    • (2012) Science , vol.338 , Issue.6109 , pp. 949-953
    • Luk, K.C.1    Kehm, V.2    Carroll, J.3    Zhang, B.4    O'Brien, P.5    Trojanowski, J.Q.6
  • 64
    • 43249114934 scopus 로고    scopus 로고
    • Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
    • 1:CAS:528:DC%2BD1cXlsFCmsrg%3D 18391962
    • Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14(5):504-6.
    • (2008) Nat Med , vol.14 , Issue.5 , pp. 504-506
    • Kordower, J.H.1    Chu, Y.2    Hauser, R.A.3    Freeman, T.B.4    Olanow, C.W.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.